In 2022, there were up to 1.2 million people with HIV (PWH) and 37,981 new cases of HIV in the United States alone. 1 While ...

The BRAAVE2020 study investigated the efficacy of switching Black Americans living with HIV to a B/F/TAF single-pill regimen.

A new study from Tulane University finds that historical race-based lending practices are still impacting health today, linking these discriminatory policies to delays in effective HIV treatment ...

The study from Tulane University found that those living in once-redlined neighborhoods see 15% longer delays in achieving successful viral suppression of HIV compared to those in non-redlined areas.

“We are talking about sex and drugs—two topics that people call taboo,” said Brigitte Quenum, UNAIDS Regional Team Lead for ...

Dolutegravir is an HIV integrase strand transfer inhibitor (INSTI) that does not require pharmacokinetic boosting, has a long half-life allowing for once-daily dosing in treatment-naive patients ...

Since the first reported case of HIV in the U.S. 43 years ago, ending HIV epidemic is possible with new medicine that may ensure long, healthy lives and prevention.

A virologist at the University of Nebraska-Lincoln, Qingsheng Li, was awarded $3.5 million to advance his work on a vaccine ...

The article, Safety of Kidney Transplantation from Donors with HIV, details findings supporting HIV-to-HIV kidney transplants as safe and just as effective as those using organs from donors without ...

Dr. John Nkengasong outlines three priorities to sustain and accelerate progress. First, ensure that those receiving ...